The Quantitative Analysis of Low-concentration (2%) ALA-PDT Assisted with Q-switch 1064-nm Nd:YAG Laser for Acne Vulgaris Treatment

Overview

Journal Lasers Med Sci

Publisher Springer

Date 2023 Oct 16

PMID 37843672

Authors

Yu-Tsung Chen

Yun-Jhen Lin

Chang-Cheng Chang

Po-Heng Liu

Yung-Hsueh Huang

Jia-Wei Shen

Meng-En Lu

Hsiu-Mei Chiang

Bor-Shyh Lin

Affiliations

Soon will be listed here.

Abstract

Conventional 5-aminolevulinic acid-photodynamic (ALA-PDT) therapy (10-20%) has been widely applied for moderate-to-severe acne. The aim of this study is to investigate the effects of non-ablative Q-switched 1064-nm Nd:YAG laser-assisted ALA-PDT with low concentration (2%) on the treatment of acne vulgaris. Enrolled patients were randomly assigned to 2 groups. One group received combined therapy of 2% ALA-PDT and non-ablative Q-switched 1064-nm Nd:YAG laser, and the other received only 2% ALA-PDT. Patients in each group had received 3-session treatments with 4-week intervals (week 0, 4, and 8). Sebum secretion, melanin index, erythema index, and transepidermal water loss (TEWL) were assessed at week 2, 8, 12, and 24. VISIA® skin image system score and global esthetic improvement scale (GAIS) were also evaluated. Twenty-four participants were enrolled and evenly randomized to two groups. Significant improvement in sebum secretion was noted in combined therapy group compared to the monotherapy group at week 12 (37.5% versus 16.3%), and the improvement would still be noted until week 24 (18.3% versus 17.4%). Combined group also showed more severe melanin index and erythema index after treatment. For VISIA® skin analysis, patients in combined group had better percentile ranking in porphyrins and red-light images. There were no significant differences in GAIS at the end of the follow-up between each group, whereas higher proportion of satisfaction was noted in combined group at week 2. With the assistance of laser, low concentrations (2%) of 5-ALA can provide effective phototoxic reactions in treating acne vulgaris. The satisfaction of patients is high with acceptable adverse effects.

References

Williams H, Dellavalle R, Garner S . Acne vulgaris. Lancet. 2011; 379(9813):361-72. DOI: 10.1016/S0140-6736(11)60321-8. View

Yamamoto A, Takenouchi K, Ito M . Impaired water barrier function in acne vulgaris. Arch Dermatol Res. 1995; 287(2):214-8. DOI: 10.1007/BF01262335. View

Pappas A, Kendall A, Brownbridge L, Batchvarova N, Nicolaou A . Seasonal changes in epidermal ceramides are linked to impaired barrier function in acne patients. Exp Dermatol. 2018; 27(8):833-836. DOI: 10.1111/exd.13499. View

de Melo M, Maia Campos P . Characterization of oily mature skin by biophysical and skin imaging techniques. Skin Res Technol. 2018; 24(3):386-395. DOI: 10.1111/srt.12441. View

Bhate K, Williams H . Epidemiology of acne vulgaris. Br J Dermatol. 2012; 168(3):474-85. DOI: 10.1111/bjd.12149. View

Shi L, Wang H, Chen K, Yan J, Yu B, Wang S . Chinese guidelines on the clinical application of 5-aminolevulinic acid-based photodynamic therapy in dermatology (2021 edition). Photodiagnosis Photodyn Ther. 2021; 35:102340. DOI: 10.1016/j.pdpdt.2021.102340. View

Hongcharu W, Taylor C, Chang Y, Aghassi D, Suthamjariya K, Anderson R . Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol. 2000; 115(2):183-92. DOI: 10.1046/j.1523-1747.2000.00046.x. View

Pollock B, Turner D, Stringer M, Bojar R, Goulden V, Stables G . Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol. 2004; 151(3):616-22. DOI: 10.1111/j.1365-2133.2004.06110.x. View

Nicklas C, Rubio R, Cardenas C, Hasson A . Comparison of efficacy of aminolaevulinic acid photodynamic therapy vs. adapalene gel plus oral doxycycline for treatment of moderate acne vulgaris-A simple, blind, randomized, and controlled trial. Photodermatol Photoimmunol Photomed. 2018; 35(1):3-10. DOI: 10.1111/phpp.12413. View

10.

Keyal U, Bhatta A, Wang X . Photodynamic therapy for the treatment of different severity of acne: A systematic review. Photodiagnosis Photodyn Ther. 2016; 14:191-9. DOI: 10.1016/j.pdpdt.2016.04.005. View

11.

Paasch U, Grunewald S . . J Dtsch Dermatol Ges. 2020; 18(12):1370-1378. DOI: 10.1111/ddg.14339_g. View

12.

Hsiao C, Yang S, Alalaiwe A, Fang J . Laser ablation and topical drug delivery: a review of recent advances. Expert Opin Drug Deliv. 2019; 16(9):937-952. DOI: 10.1080/17425247.2019.1649655. View

13.

Haedersdal M, Erlendsson A, Paasch U, Anderson R . Translational medicine in the field of ablative fractional laser (AFXL)-assisted drug delivery: A critical review from basics to current clinical status. J Am Acad Dermatol. 2016; 74(5):981-1004. DOI: 10.1016/j.jaad.2015.12.008. View

14.

Searle T, Ali F, Al-Niaimi F . Lessons Learned from the First Decade of Laser-Assisted Drug Delivery. Dermatol Ther (Heidelb). 2021; 11(1):93-104. PMC: 7858718. DOI: 10.1007/s13555-020-00478-5. View

15.

De Filippis A, Perfetto B, Guerrera L, Oliviero G, Baroni A . Q-switched 1064 nm Nd-Yag nanosecond laser effects on skin barrier function and on molecular rejuvenation markers in keratinocyte-fibroblasts interaction. Lasers Med Sci. 2018; 34(3):595-605. DOI: 10.1007/s10103-018-2635-1. View

16.

Yin R, Hao F, Deng J, Yang X, Yan H . Investigation of optimal aminolaevulinic acid concentration applied in topical aminolaevulinic acid-photodynamic therapy for treatment of moderate to severe acne: a pilot study in Chinese subjects. Br J Dermatol. 2010; 163(5):1064-71. DOI: 10.1111/j.1365-2133.2010.09860.x. View

17.

Taylor M, Gonzalez M . The practicalities of photodynamic therapy in acne vulgaris. Br J Dermatol. 2009; 160(6):1140-8. DOI: 10.1111/j.1365-2133.2009.09054.x. View

18.

Divaris D, Kennedy J, Pottier R . Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. Am J Pathol. 1990; 136(4):891-7. PMC: 1877631. View

19.

Kennedy J, Pottier R . Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 1992; 14(4):275-92. DOI: 10.1016/1011-1344(92)85108-7. View

20.

Tierney E, Barker A, Ahdout J, William Hanke C, Moy R, Kouba D . Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatol Surg. 2009; 35(5):725-46. DOI: 10.1111/j.1524-4725.2009.01117.x. View